PHARMACOECONOMIC ISSUES OF ADALIMUMAB THERAPY IN JUVENILE IDIOPATHIC ARTHRITIS

Background. Juvenile idiopathic arthritis (JIA) is the most common type of arthritis in children and is associated with reduced quality of life and increased health care costs. Objective. To evaluate the cost effectiveness of the tumour necrosis factor inhibitor adalimumab (ADA) vs. non-biologic the...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: K. Simpson, N. Marlow, J. Shaw, А. V. Rudakova
Médium: Artigo
Jazyk:Inglês
Vydáno: Paediatrician Publishers, LLC 2012-08-01
Edice:Pediatričeskaâ Farmakologiâ
Témata:
juvenile idiopathic arthritis
adalimumab
cost-effectiveness analysis
On-line přístup:https://www.pedpharma.ru/jour/article/view/302
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky